Drug intelligence / Profile preview

rocuronium + vecuronium

Development stage: Preclinical
Lead developer: Organon
Modality: Small Molecules
Administration: Intravenous

Overview

A combination of two steroidal non-depolarizing neuromuscular blocking agents that act synergistically during the early part of their action. This combination provides comparable conditions for tracheal intubation as an equipotent dose of rocuronium alone, with excellent intubation conditions achieved in a higher percentage of patients compared to either drug used individually. Both drugs work by competitively binding to nicotinic cholinergic receptors at the motor end plate, preventing muscle contraction.

Targets

Muscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on rocuronium + vecuronium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rocuronium + vecuronium.

Explore the full profile